Categories: Healthcare

FDA Approves USA’s First Interchangeable Biosimilar Insulin Product for Diabetes

The Food and Drug Administration of the United States have now approved the first interchangeable biosimilar insulin product, that is mainly indicated for the purpose of improving the glycemic control in the pediatric and adults affected from the Type 1 diabetes and in the adults affected with Type 2 diabetes.

The product ‘Semglee’ has been both interchangeable and biosimilar along with the reference product known as Lantus, which has been a long-acting insulin analog, and the Semglee has been the first interchangeable biosimilar product, that has been approved in the United States for the purpose of treating the patients suffering from diabetes, and the approval of these types of insulin products can be responsible in providing the patients with the options such as safe, high-quality, safe and low cost for the treatment of diabetes.

Janet Woodcock, acting commissioner of US FDA said, this has been a great news for the people who are relying on the insulin daily for the treatment of diabetes, as the interchangeable biosimilar and biosimilar products generally have the potential for greatly decreasing the costs of the healthcare.

Janet Woodcock also said, this approval has been the longstanding commitment of the US FDA for supporting a competitive marketplace for the biological products and it has also been ultimately empowering the patients by providing help in increasing the access of the patients to the high-quality, safe and effective medications at potential low cost, and these products of insulin might also be replaced by the reference product without any kind of intervention of the prescribing personnel.

Writing is a medium to express feelings and convey facts. A creative mind never rests in peace and this amazing platform gives me the freedom to write about what I like most.

I’ve been a writer/blogger for the last twelve years and have covered technology-related topics. However, I also have considerable years of experience in writing for various domains – Technology, Beauty, Fashion, Pharmaceutical, human psychology etc. Technology is my forte.

I’ve handled many interesting projects. Writing is my passion. As an author, I’ve learned a lot in my long journey of penning down my thoughts!

Recent Posts

Premier League Clubs Agree to Remove Gambling Sponsorships from Team Shirts

After discussions with the government, Premier League clubs have agreed to stop sponsoring their front…

1 year ago

Russia’s Novatek to Gain Shell’s Stake in Sakhalin-2

Analysts reported that Novatek, a Russian natural gas producer, acquired Shell's stake in the Sakhalin-2…

1 year ago

Volkswagen Launches New-Gen Electric Motor to Power its “ID” Family

The electric drivetrain of the next generation for Volkswagen's "ID" has been unveiled. Family EV.…

1 year ago

Egg Prices to Reach Record High in 2023 Globally

According to research, global egg prices are expected to remain at an all-time high until…

1 year ago

Audi Selects Ohme as Smart Charger Partner in UK

Ohme becomes Audi's Official UK Smart Charger Partner Ohme has been selected as Audi's new…

1 year ago

General Motors Invests EnergyX to Unlock Lithium Supply in North America

GM Ventures has signed a strategic agreement to develop EnergyX's lithium extraction and refinery technology,…

1 year ago